

Friedemann Paul

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5448003/publications.pdf>

Version: 2024-02-01

480
papers

27,239
citations

7251

80
h-index

12272

138
g-index

509
all docs

509
docs citations

509
times ranked

21700
citing authors

#	ARTICLE	IF	CITATIONS
1	Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2022, 28, 757-767.	1.4	3
2	Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry. <i>Multiple Sclerosis Journal</i> , 2022, 28, 865-871.	1.4	8
3	Modular deep neural networks for automatic quality control of retinal optical coherence tomography scans. <i>Computers in Biology and Medicine</i> , 2022, 141, 104822.	3.9	10
4	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 188-195.	0.9	13
5	In vivo stiffness of multiple sclerosis lesions is similar to that of normal-appearing white matter. <i>Acta Biomaterialia</i> , 2022, 138, 410-421.	4.1	9
6	Frailty and Falls in People Living With Multiple Sclerosis. <i>Archives of Physical Medicine and Rehabilitation</i> , 2022, 103, 952-957.	0.5	6
7	Immune signature of multiple sclerosis-associated depression. <i>Brain, Behavior, and Immunity</i> , 2022, 100, 174-182.	2.0	6
8	OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103525.	0.9	36
9	Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103466.	0.9	3
10	Proposal for Post Hoc Quality Control in Instrumented Motion Analysis Using Markerless Motion Capture: Development and Usability Study. <i>JMIR Human Factors</i> , 2022, 9, e26825.	1.0	2
11	Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry. <i>Neurology and Therapy</i> , 2022, 11, 319-336.	1.4	2
12	State-dependent signatures of anti-N-methyl-D-aspartate receptor encephalitis. <i>Brain Communications</i> , 2022, 4, fcab298.	1.5	11
13	Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 192-202.	2.8	17
14	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease. <i>Neurology</i> , 2022, 98, .	1.5	14
15	Teriflunomide Preserves Neuronal Activity and Protects Mitochondria in Brain Slices Exposed to Oxidative Stress. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1538.	1.8	10
16	Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4+ T Cells following BNT162b2 Vaccination in the Elderly. <i>Journal of Immunology</i> , 2022, 208, 1001-1005.	0.4	16
17	Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	32
18	Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	32

#	ARTICLE	IF	CITATIONS
19	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgGâ€“Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	64
20	Anatomical and functional visual network patterns in progressive multiple sclerosis. <i>Human Brain Mapping</i> , 2022, 43, 1590-1597.	1.9	2
21	Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	32
22	Diagnostic efficacy of the magnetic resonance T1w/T2w ratio for the middle cerebellar peduncle in multiple system atrophy and spinocerebellar ataxia: A preliminary study. <i>PLoS ONE</i> , 2022, 17, e0267024.	1.1	1
23	CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage. <i>Journal of Neuroinflammation</i> , 2022, 19, 86.	3.1	13
24	Different Impact of Gadopentetate and Gadobutrol on Inflammation-Promoted Retention and Toxicity of Gadolinium Within the Mouse Brain. <i>Investigative Radiology</i> , 2022, 57, 677-688.	3.5	7
25	Intraretinal Layer Segmentation Using Cascaded Compressed U-Nets. <i>Journal of Imaging</i> , 2022, 8, 139.	1.7	7
26	Preventing Axonal Sodium Overload or Mitochondrial Calcium Uptake Protects Axonal Mitochondria from Oxidative Stress-Induced Alterations. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-13.	1.9	2
27	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1859-1870.	1.4	14
28	Prefrontal-amygdala emotion regulation and depression in multiple sclerosis. <i>Brain Communications</i> , 2022, 4, .	1.5	5
29	Longitudinal Retinal Changes in <sc>MOGAD</sc>. <i>Annals of Neurology</i> , 2022, 92, 476-485.	2.8	20
30	Prediction of high and low disease activity in early MS patients using multiple kernel learning identifies importance of lateral ventricle intensity. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732211097.	0.5	3
31	SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 960-971.	0.9	20
32	Functional connectivity alterations of striato-cortical circuits in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1469-1470.	1.4	1
33	Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD â€“ Commentary. <i>Multiple Sclerosis Journal</i> , 2021, 27, 16-18.	1.4	2
34	Magnetic resonance T1w/T2w ratio in the middle cerebellar peduncle might be a sensitive biomarker for multiple system atrophy. <i>European Radiology</i> , 2021, 31, 4277-4284.	2.3	8
35	Anti-MOG antibodyâ€“associated disorders: differences in clinical profiles and prognosis in Japan and Germany. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 377-383.	0.9	18
36	The Worm-Specific Immune Response in Multiple Sclerosis Patients Receiving Controlled <i>Trichuris suis</i> Ova Immunotherapy. <i>Life</i> , 2021, 11, 101.	1.1	9

#	ARTICLE	IF	CITATIONS
37	A novel investigation method for axonal damage in neuromyelitis optica spectrum disorder: In vivo corneal confocal microscopy. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732199806.	0.5	1
38	Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla. <i>Journal of Visualized Experiments</i> , 2021, , .	0.2	3
39	Pain, depression, and quality of life in adults with MOGâ€antibodyâ€associated disease. <i>European Journal of Neurology</i> , 2021, 28, 1645-1658.	1.7	11
40	Sensitivity analysis of the primary endpoint from the N-MOMentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2052-2061.	1.4	11
41	Epigallocatechin Gallate in Progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	12
42	Practical recognition tools of immunoglobulinÂG serum antibodies against the myelin oligodendrocyte glycoproteinâ€positive optic neuritis and its clinical implications. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 42-53.	0.5	4
43	Cultural bias in motor function patterns: Potential relevance for predictive, preventive, and personalized medicine. <i>EPMA Journal</i> , 2021, 12, 91-101.	3.3	4
44	Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	16
45	Foveal changes in aquaporinâ€4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive. <i>European Journal of Neurology</i> , 2021, 28, 2280-2293.	1.7	14
46	Disability Outcomes in the N-MOMentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	20
47	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. <i>Annals of Neurology</i> , 2021, 89, 895-910.	2.8	72
48	Accelerating clinical research in neuromyelitis optica spectrum disorders. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 89-91.	0.5	3
49	Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2180-2190.	1.4	12
50	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. <i>Neurology</i> , 2021, 97, 68-79.	1.5	96
51	Retinal Thickness Analysis in Progressive Multiple Sclerosis Patients Treated With Epigallocatechin Gallate: Optical Coherence Tomography Results From the SUPREMES Study. <i>Frontiers in Neurology</i> , 2021, 12, 615790.	1.1	7
52	Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity. <i>Neurodegenerative Disease Management</i> , 2021, 11, 143-153.	1.2	3
53	Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	41
54	AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110068.	0.5	6

#	ARTICLE	IF	CITATIONS
55	Artificial intelligence extension of the OSCARâ€B criteria. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1528-1542.	1.7	33
56	Simultaneous T 2 and mapping of multiple sclerosis lesions with radial RAREâ€EPI. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 1383-1402.	1.9	2
57	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. <i>Journal of Neuroinflammation</i> , 2021, 18, 105.	3.1	44
58	Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry. <i>Scientific Reports</i> , 2021, 11, 13340.	1.6	30
59	Association of a Marker of <i>N</i> -Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration. <i>JAMA Neurology</i> , 2021, 78, 842.	4.5	15
60	Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells. <i>Neurotherapeutics</i> , 2021, 18, 1783-1797.	2.1	6
61	Clinical and neuroimaging findings in MOGADâ€MRI and OCT. <i>Clinical and Experimental Immunology</i> , 2021, 206, 266-281.	1.1	24
62	Cognitive Impairment in Multiple System Atrophy Is Related to White Matter Damage Detected by the T1-Weighted/T2-Weighted Ratio. <i>European Neurology</i> , 2021, 84, 435-443.	0.6	5
63	Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	65
64	Cross-reactive CD4 ⁺ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. <i>Science</i> , 2021, 374, eabh1823.	6.0	221
65	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103080.	0.9	7
66	Increased Serum Neurofilament Light and Thin Ganglion Cellâ€Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	29
67	Retinal Optical Coherence Tomography in Neuromyelitis Optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	47
68	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.	4.9	261
69	Identification of the gliogenic state of human neural stem cells to optimize in vitro astrocyte differentiation. <i>Journal of Neuroscience Methods</i> , 2021, 361, 109284.	1.3	5
70	Retinal optical coherence tomography and magnetic resonance imaging in neuromyelitis optica spectrum disorders and MOG-antibody associated disorders: an updated review. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1101-1123.	1.4	7
71	Characteristics of secondary progressive multiple sclerosis: Disease activity and provision of care in Germany â€ A registry-based/multicentric cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103281.	0.9	6
72	C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD. <i>Journal of Neuroimmunology</i> , 2021, 360, 577699.	1.1	16

#	ARTICLE	IF	CITATIONS
73	<i>In vivo</i> detection of terflunomide-derived fluorine signal during neuroinflammation using fluorine MR spectroscopy. <i>Theranostics</i> , 2021, 11, 2490-2504.	4.6	10
74	A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110143.	1.5	16
75	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study. <i>NeuroImage: Clinical</i> , 2021, 30, 102608.	1.4	9
76	N2 year in review. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e925.	3.1	3
77	Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2235-2251.	1.7	36
78	Neural Processes of Psychological Stress and Relaxation Predict the Future Evolution of Quality of Life in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 753107.	1.1	7
79	Patch individual filter layers in CNNs to harness the spatial homogeneity of neuroimaging data. <i>Scientific Reports</i> , 2021, 11, 24447.	1.6	3
80	Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders. <i>Acta Neurologica Belgica</i> , 2020, 120, 223-225.	0.5	11
81	Brain Iron and Metabolic Abnormalities in C19orf12 Mutation Carriers: A 7.0 Tesla MRI Study in Mitochondrial Membrane Protein-associated Neurodegeneration. <i>Movement Disorders</i> , 2020, 35, 142-150.	2.2	16
82	Ketogenic diet and fasting diet as Nutritional Approaches in Multiple Sclerosis (NAMS): protocol of a randomized controlled study. <i>Trials</i> , 2020, 21, 3.	0.7	55
83	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. <i>Frontiers in Neurology</i> , 2020, 11, 579438.	1.1	9
84	Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102485.	0.9	26
85	Instrumental Assessment of Stepping in Place Captures Clinically Relevant Motor Symptoms of Parkinson's Disease. <i>Sensors</i> , 2020, 20, 5465.	2.1	8
86	Neuromyelitis optica. <i>Nature Reviews Disease Primers</i> , 2020, 6, 85.	18.1	232
87	N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation. <i>Journal of Biological Chemistry</i> , 2020, 295, 17413-17424.	1.6	29
88	Blunted neural and psychological stress processing predicts future grey matter atrophy in multiple sclerosis. <i>Neurobiology of Stress</i> , 2020, 13, 100244.	1.9	10
89	Genetic determinants of the humoral immune response in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e827.	3.1	7
90	Visual system damage and network maladaptation are associated with cognitive performance in neuromyelitis optica spectrum disorders.. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102406.	0.9	9

#	ARTICLE	IF	CITATIONS
91	Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis. <i>Scientific Reports</i> , 2020, 10, 8776.	1.6	4
92	Functionally Relevant Maculopathy and Optic Atrophy in Spinocerebellar Ataxia Type 1. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 502-508.	0.8	7
93	Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. <i>Brain</i> , 2020, 143, 3574-3588.	3.7	110
94	Aggressive multiple sclerosis: a matter of measurement and timing. <i>Brain</i> , 2020, 143, e97-e97.	3.7	8
95	Conduction delays in the visual pathways of progressive multiple sclerosis patients covary with brain structure. <i>NeuroImage</i> , 2020, 221, 117204.	2.1	14
96	Emerging drugs for the treatment of neuromyelitis optica. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 285-297.	1.0	14
97	Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102579.	0.9	14
98	Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study. <i>Frontiers in Neurology</i> , 2020, 11, 499910.	1.1	14
99	Altered Coupling of Psychological Relaxation and Regional Volume of Brain Reward Areas in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 568850.	1.1	3
100	Teriflunomide preserves peripheral nerve mitochondria from oxidative stress-mediated alterations. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232094477.	1.1	9
101	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 261.	3.1	84
102	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 262.	3.1	44
103	Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1628-1641.	1.7	3
104	Sex differences in brain atrophy in multiple sclerosis. <i>Biology of Sex Differences</i> , 2020, 11, 49.	1.8	51
105	10th Anniversary of the European Association for Predictive, Preventive and Personalised (3P) Medicine - EPMA World Congress Supplement 2020. <i>EPMA Journal</i> , 2020, 11, 1-133.	3.3	34
106	Quantitative Multi-Parameter Mapping Optimized for the Clinical Routine. <i>Frontiers in Neuroscience</i> , 2020, 14, 611194.	1.4	19
107	Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. <i>Frontiers in Neurology</i> , 2020, 11, 778.	1.1	37
108	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020, 10, e035397.	0.8	10

#	ARTICLE	IF	CITATIONS
109	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 681-686.	0.9	66
110	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020, 56, 102807.	2.7	67
111	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	0.9	110
112	Is APOE ϵ 4 associated with cognitive performance in early MS?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e728.	3.1	11
113	Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. <i>Nature Communications</i> , 2020, 11, 2856.	5.8	50
114	Identifying Progression in Multiple Sclerosis: New Perspectives. <i>Annals of Neurology</i> , 2020, 88, 438-452.	2.8	67
115	Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Neurology</i> , 2020, 11, 450.	1.1	29
116	Impact of treatment on cellular immunophenotype in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	17
117	Wisdom of the expert crowd prediction of response for 3 neurology randomized trials. <i>Neurology</i> , 2020, 95, e488-e498.	1.5	5
118	Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1061-1072.	1.4	15
119	Vitamin D and Disease Severity in Multiple Sclerosis—Baseline Data From the Randomized Controlled Trial (EVIDIMS). <i>Frontiers in Neurology</i> , 2020, 11, 129.	1.1	15
120	Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) — preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial. <i>BMC Neurology</i> , 2020, 20, 75.	0.8	10
121	Investigation of Visual System Involvement in Spinocerebellar Ataxia Type 14. <i>Cerebellum</i> , 2020, 19, 469-482.	1.4	3
122	Altered fovea in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	50
123	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. <i>Frontiers in Neurology</i> , 2020, 11, 501.	1.1	216
124	DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning. <i>PLoS Computational Biology</i> , 2020, 16, e1007616.	1.5	54
125	Binding patterns and functional properties of human antibodies to AQP4 and MOG on murine optic nerve and retina. <i>Journal of Neuroimmunology</i> , 2020, 342, 577194.	1.1	2
126	Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102027.	0.9	11

#	ARTICLE	IF	CITATIONS
127	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020, 94, e407-e418.	1.5	36
128	Prodromal headache in MOG-antibody positive optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101965.	0.9	41
129	Antibody signatures in patients with histopathologically defined multiple sclerosis patterns. <i>Acta Neuropathologica</i> , 2020, 139, 547-564.	3.9	11
130	Association Between Fatigue and Motor Exertion in Patients With Multiple Sclerosis—a Prospective Study. <i>Frontiers in Neurology</i> , 2020, 11, 208.	1.1	18
131	Longitudinal ultra-high field MRI of brain lesions in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102066.	0.9	4
132	Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders. <i>European Radiology</i> , 2020, 30, 5048-5058.	2.3	9
133	N2 year in review. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e644.	3.1	1
134	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. <i>Brain</i> , 2020, 143, 1127-1142.	3.7	29
135	Evaluation of the “ring sign”™ and the “core sign”™ as a magnetic resonance imaging marker of disease activity and progression in clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732091548.	0.5	25
136	Cortical topological network changes following optic neuritis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e687.	3.1	8
137	Considerations for Mean Upper Cervical Cord Area Implementation in a Longitudinal MRI Setting: Methods, Interrater Reliability, and MRI Quality Control. <i>American Journal of Neuroradiology</i> , 2020, 41, 343-350.	1.2	7
138	Transdiagnostic hippocampal damage patterns in neuroimmunological disorders. <i>NeuroImage: Clinical</i> , 2020, 28, 102515.	1.4	11
139	Transient enlargement of brain ventricles during relapsing-remitting multiple sclerosis and experimental autoimmune encephalomyelitis. <i>JCI Insight</i> , 2020, 5, .	2.3	13
140	High-dose vitamin D supplementation in multiple sclerosis “ results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732090347.	0.5	27
141	An International Standardized Magnetic Resonance Imaging Protocol for Diagnosis and Follow-up of Patients with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2020, 22, 226-232.	0.4	14
142	Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 1446.	4.5	119
143	Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. <i>Journal of Neuroinflammation</i> , 2019, 16, 154.	3.1	61
144	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 724-735.	4.9	79

#	ARTICLE	IF	CITATIONS
145	Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study. <i>Brain Communications</i> , 2019, 1, fcz026.	1.5	15
146	EMR-integrated minimal core dataset for routine health care and multiple research settings: A case study for neuroinflammatory demyelinating diseases. <i>PLoS ONE</i> , 2019, 14, e0223886.	1.1	10
147	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , 2019, 394, 1352-1363.	6.3	433
148	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731987158.	0.5	34
149	Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis. <i>Neurology</i> , 2019, 93, e1439-e1451.	1.5	43
150	Uncovering convolutional neural network decisions for diagnosing multiple sclerosis on conventional MRI using layer-wise relevance propagation. <i>NeuroImage: Clinical</i> , 2019, 24, 102003.	1.4	93
151	Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e572.	3.1	133
152	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. <i>Brain</i> , 2019, 142, 1858-1875.	3.7	303
153	Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy. <i>BMC Neurology</i> , 2019, 19, 118.	0.8	1
154	Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A Review of Clinical and Neuroradiological Features. <i>Frontiers in Neurology</i> , 2019, 10, 608.	1.1	42
155	Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1156-1164.	0.9	20
156	Olfactory and Gustatory Dysfunction in Patients With Autoimmune Encephalitis. <i>Frontiers in Neurology</i> , 2019, 10, 480.	1.1	7
157	Neural mechanisms of perceptual decision-making and their link to neuropsychiatric symptoms in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 139-145.	0.9	4
158	Vision and Vision-Related Measures in Progressive Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 455.	1.1	17
159	MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9671-9676.	3.3	42
160	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 841.	4.5	48
161	Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 334.	1.1	31
162	Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. <i>Annals of Neurology</i> , 2019, 85, 618-629.	2.8	104

#	ARTICLE	IF	CITATIONS
163	N2 year in review and message from the editor to our reviewers. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e525.	3.1	1
164	Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e541.	3.1	15
165	Contactless recording of sleep apnea and periodic leg movements by nocturnal 3-D-video and subsequent visual perceptive computing. <i>Scientific Reports</i> , 2019, 9, 16812.	1.6	15
166	Multi-parameter immune profiling of peripheral blood mononuclear cells by multiplexed single-cell mass cytometry in patients with early multiple sclerosis. <i>Scientific Reports</i> , 2019, 9, 19471.	1.6	37
167	Low-Density Granulocytes Are a Novel Immunopathological Feature in Both Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Immunology</i> , 2019, 10, 2725.	2.2	23
168	Suggestions for improving the design of clinical trials in multiple sclerosis—results of a systematic analysis of completed phase III trials. <i>EPMA Journal</i> , 2019, 10, 425-436.	3.3	31
169	Increased Retention of Gadolinium in the Inflamed Brain After Repeated Administration of Gadopentetate Dimeglumine. <i>Investigative Radiology</i> , 2019, 54, 617-626.	3.5	30
170	Normative Data and Minimally Detectable Change for Inner Retinal Layer Thicknesses Using a Semi-automated OCT Image Segmentation Pipeline. <i>Frontiers in Neurology</i> , 2019, 10, 1117.	1.1	36
171	Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 64-68.	0.9	44
172	Novel uses of retinal imaging with optical coherence tomography in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 31-43.	1.4	44
173	Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1926-1936.	1.4	47
174	Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation. <i>Nature Communications</i> , 2019, 10, 217.	5.8	56
175	Sex differences in autoimmune disorders of the central nervous system. <i>Seminars in Immunopathology</i> , 2019, 41, 177-188.	2.8	74
176	Gadolinium in human brain sections and colocalization with other elements. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e515.	3.1	22
177	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). <i>Journal of Neurology</i> , 2019, 266, 386-397.	1.8	24
178	Association of smoking but not HLA-DRB1*15:01, <i>APOE</i> or body mass index with brain atrophy in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 661-668.	1.4	12
179	Multiple sclerosis—related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex. <i>Multiple Sclerosis Journal</i> , 2019, 25, 554-564.	1.4	69
180	Flammer Syndrome and Autoimmune Inflammatory Conditions of the Central Nervous System: Multifactorial Interrelations. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2019, , 145-163.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Automatic quality evaluation as assessment standard for optical coherence tomography. , 2019, , .		2
182	Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opinion on Investigational Drugs, 2018, 27, 265-271.	1.9	40
183	Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy. EPMA Journal, 2018, 9, 21-33.	3.3	75
184	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nature Reviews Neurology, 2018, 14, 199-213.	4.9	157
185	Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome. JAMA Neurology, 2018, 75, 1071.	4.5	72
186	The effectiveness of acupuncture and mindfulness-based stress reduction (MBSR) for patients with multiple sclerosis associated fatigue â€“ A study protocol and its rationale for a randomized controlled trial. European Journal of Integrative Medicine, 2018, 20, 6-15.	0.8	2
187	Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon. Journal of the Neurological Sciences, 2018, 387, 60-69.	0.3	5
188	Worldwide prevalence of neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 555-556.	0.9	87
189	Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis. JAMA Neurology, 2018, 75, 287.	4.5	39
190	Pursuing functional connectivity in NMDAR1 autoantibody carriers â€“ Authors' reply. Lancet Psychiatry, the, 2018, 5, 22.	3.7	1
191	Safety and preliminary efficacy of deep transcranial magnetic stimulation in MS-related fatigue. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e423.	3.1	52
192	Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization. JAMA Neurology, 2018, 75, 296.	4.5	34
193	Magnetic resonance imaging findings at the first episode of acute optic neuritis. Multiple Sclerosis and Related Disorders, 2018, 20, 30-36.	0.9	23
194	Frequent retinal ganglion cell damage after acute optic neuritis. Multiple Sclerosis and Related Disorders, 2018, 22, 141-147.	0.9	30
195	Multicenter reliability of semiautomatic retinal layer segmentation using OCT. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e449.	3.1	76
196	Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e446.	3.1	54
197	Brain activity, regional gray matter loss, and decision-making in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1163-1173.	1.4	21
198	Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2018, 24, 1737-1742.	1.4	41

#	ARTICLE	IF	CITATIONS
199	Superficial white matter damage in anti-NMDA receptor encephalitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 518-525.	0.9	55
200	A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 330-338.	0.9	23
201	Self-perception and determinants of color vision in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 145-152.	1.4	8
202	Leptomeningeal and Intraparenchymal Blood Barrier Disruption in a MOG-IgG-Positive Patient. <i>Case Reports in Neurological Medicine</i> , 2018, 2018, 1-3.	0.3	7
203	The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis. <i>Journal of Neuro-Ophthalmology</i> , 2018, 38, 494-501.	0.4	15
204	Ozanimod for the treatment of relapsing remitting multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 2073-2086.	0.9	34
205	Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. <i>Frontiers in Neurology</i> , 2018, 9, 888.	1.1	194
206	Metabolic, Mental and Immunological Effects of Normoxic and Hypoxic Training in Multiple Sclerosis Patients: A Pilot Study. <i>Frontiers in Immunology</i> , 2018, 9, 2819.	2.2	22
207	Pro-inflammatory Monocyte Phenotype and Cell-Specific Steroid Signaling Alterations in Unmedicated Patients With Major Depressive Disorder. <i>Frontiers in Immunology</i> , 2018, 9, 2693.	2.2	40
208	Venoplasty in MS. <i>Neurology</i> , 2018, 91, 815-816.	1.5	0
209	Objective assessment of a relative afferent pupillary defect by B-mode ultrasound. <i>PLoS ONE</i> , 2018, 13, e0202774.	1.1	4
210	Racial differences in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2018, 91, e2089-e2099.	1.5	140
211	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	3.1	173
212	MRI Markers and Functional Performance in Patients With CIS and MS: A Cross-Sectional Study. <i>Frontiers in Neurology</i> , 2018, 9, 718.	1.1	14
213	Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging. <i>PLoS ONE</i> , 2018, 13, e0202918.	1.1	36
214	Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731879668.	0.5	40
215	Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies. <i>EPMA Journal</i> , 2018, 9, 249-256.	3.3	31
216	Temporal visual resolution and disease severity in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e492.	3.1	15

#	ARTICLE	IF	CITATIONS
217	Comparison of probabilistic tractography and tract-based spatial statistics for assessing optic radiation damage in patients with autoimmune inflammatory disorders of the central nervous system. <i>NeuroImage: Clinical</i> , 2018, 19, 538-550.	1.4	40
218	Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1259-1265.	0.9	100
219	MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 66-72.	0.9	158
220	Omics-Based Approach Reveals Complement-Mediated Inflammation in Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS). <i>Frontiers in Immunology</i> , 2018, 9, 741.	2.2	10
221	VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e475.	3.1	14
222	MRI-Based Methods for Spinal Cord Atrophy Evaluation: A Comparison of Cervical Cord Cross-Sectional Area, Cervical Cord Volume, and Full Spinal Cord Volume in Patients with Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders. <i>American Journal of Neuroradiology</i> , 2018, 39, 1362-1368.	1.2	13
223	Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 78-82.	0.9	38
224	Optical coherence tomography in acute optic neuritis: A population-based study. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 566-573.	1.0	44
225	7 Tesla MRI of Balo's concentric sclerosis versus multiple sclerosis lesions. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 900-912.	1.7	14
226	Beyond the limbic system: disruption and functional compensation of large-scale brain networks in patients with anti-LGI1 encephalitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1191-1199.	0.9	48
227	Less Is More – Estimation of the Number of Strides Required to Assess Gait Variability in Spatially Confined Settings. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 435.	1.7	41
228	Optic nerve head three-dimensional shape analysis. <i>Journal of Biomedical Optics</i> , 2018, 23, 1.	1.4	8
229	Active contour method for ILM segmentation in ONH volume scans in retinal OCT. <i>Biomedical Optics Express</i> , 2018, 9, 6497.	1.5	11
230	Subjective and objective assessment of physical activity in multiple sclerosis and their relation to health-related quality of life. <i>BMC Neurology</i> , 2017, 17, 10.	0.8	18
231	Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 11, 45-50.	0.9	89
232	Inflammation-induced brain endothelial activation leads to uptake of electrostatically stabilized iron oxide nanoparticles via sulfated glycosaminoglycans. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 1411-1421.	1.7	18
233	The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 mice. <i>BMC Neuroscience</i> , 2017, 18, 19.	0.8	44
234	Alzheimer's disease: Elevated pigment epithelium-derived factor in the cerebrospinal fluid is mostly of systemic origin. <i>Journal of the Neurological Sciences</i> , 2017, 375, 123-128.	0.3	8

#	ARTICLE	IF	CITATIONS
235	Microstructural visual system changes in AQP4-antibodyâ€‘seropositive NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e334.	3.1	128
236	Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. <i>Scientific Reports</i> , 2017, 7, 43718.	1.6	35
237	Singleâ€‘subject independent component analysisâ€‘based intensity normalization in nonâ€‘quantitative multiâ€‘modal structural MRI. <i>Human Brain Mapping</i> , 2017, 38, 3615-3622.	1.9	1
238	Contribution of blood vessels to retinal nerve fiber layer thickness in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e338.	3.1	19
239	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e343.	3.1	55
240	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	0.9	123
241	Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e339.	3.1	32
242	Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies. <i>JAMA Neurology</i> , 2017, 74, 50.	4.5	214
243	What should a person with relapsing-remitting multiple sclerosis know? â€‘ Focus group and survey data of a risk knowledge questionnaire (RIKNO 2.0). <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 186-195.	0.9	9
244	High risk of postpartum relapses in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2017, 89, 2238-2244.	1.5	59
245	Fatigue as a symptom or comorbidity of neurological diseases. <i>Nature Reviews Neurology</i> , 2017, 13, 662-675.	4.9	270
246	Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 198-201.	0.9	36
247	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology, The</i> , 2017, 16, 797-812.	4.9	397
248	Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis: an observational study. <i>Lancet Psychiatry,the</i> , 2017, 4, 768-774.	3.7	111
249	Synapsin-antibodies in psychiatric and neurological disorders: Prevalence and clinical findings. <i>Brain, Behavior, and Immunity</i> , 2017, 66, 125-134.	2.0	15
250	Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. <i>Journal of Neurology</i> , 2017, 264, 1370-1380.	1.8	55
251	Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system. <i>EPMA Journal</i> , 2017, 8, 279-294.	3.3	35
252	Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. <i>EPMA Journal</i> , 2017, 8, 313-325.	3.3	94

#	ARTICLE	IF	CITATIONS
253	Olfactory dysfunction in patients with primary progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e369.	3.1	13
254	Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1847-1853.	1.4	65
255	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1092-1103.	1.4	60
256	Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder. <i>European Radiology</i> , 2017, 27, 2206-2215.	2.3	16
257	Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2017, 23, 963-972.	1.4	65
258	CuBe: parametric modeling of 3D foveal shape using cubic B-splines. <i>Biomedical Optics Express</i> , 2017, 8, 4181.	1.5	16
259	Dynamics and heterogeneity of brain damage in multiple sclerosis. <i>PLoS Computational Biology</i> , 2017, 13, e1005757.	1.5	33
260	Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. <i>Journal of Neuroinflammation</i> , 2017, 14, 172.	3.1	16
261	The chronically inflamed central nervous system provides niches for long-lived plasma cells. <i>Acta Neuropathologica Communications</i> , 2017, 5, 88.	2.4	54
262	Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis. <i>PLoS ONE</i> , 2017, 12, e0175279.	1.1	29
263	B-mode ultrasound assessment of pupillary function: Feasibility, reliability and normal values. <i>PLoS ONE</i> , 2017, 12, e0189016.	1.1	15
264	Maximum walking speed in multiple sclerosis assessed with visual perceptive computing. <i>PLoS ONE</i> , 2017, 12, e0189281.	1.1	29
265	Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod. <i>Case Reports in Neurological Medicine</i> , 2016, 2016, 1-8.	0.3	13
266	Poor Sleep in Multiple Sclerosis Correlates with Beck Depression Inventory Values, but Not with Polysomnographic Data. <i>Sleep Disorders</i> , 2016, 2016, 1-5.	0.8	17
267	Longitudinal Intravital Imaging of the Retina Reveals Long-term Dynamics of Immune Infiltration and Its Effects on the Glial Network in Experimental Autoimmune Uveoretinitis, without Evident Signs of Neuronal Dysfunction in the Ganglion Cell Layer. <i>Frontiers in Immunology</i> , 2016, 7, 642.	2.2	20
268	Analysis of Lymphocytic DNA Damage in Early Multiple Sclerosis by Automated Gamma-H2AX and 53BP1 Foci Detection: A Case Control Study. <i>PLoS ONE</i> , 2016, 11, e0147968.	1.1	9
269	RETINAL LESION EVOLUTION IN SUSAC SYNDROME. <i>Retina</i> , 2016, 36, 366-374.	1.0	25
270	Higher-resolution MR elastography reveals early mechanical signatures of neuroinflammation in patients with clinically isolated syndrome. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, spcone-spcone.	1.9	2

#	ARTICLE	IF	CITATIONS
271	Ranking of Dystonia Severity by Pairwise Video Comparison. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 587-595.	0.8	0
272	Widespread inflammation in CLIPPERS syndrome indicated by autopsy and ultra-high-field 7T MRI. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e226.	3.1	47
273	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1005-1015.	0.9	228
274	The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue. <i>EPMA Journal</i> , 2016, 7, 25.	3.3	61
275	A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms. <i>Cell Reports</i> , 2016, 15, 2136-2146.	2.9	371
276	The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. <i>Neurology</i> , 2016, 86, 2303-2309.	1.5	331
277	Fine specificity of the antibody response to Epstein-Barr nuclear antigen-2 and other Epstein-Barr virus proteins in patients with clinically isolated syndrome: A peptide microarray-based case-control study. <i>Journal of Neuroimmunology</i> , 2016, 297, 56-62.	1.1	11
278	Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0-Tesla MRI clinical study. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2016, 29, 535-541.	1.1	9
279	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German "Austrian retrospective multicenter study in patients with a clinically isolated syndrome. <i>Journal of Neurology</i> , 2016, 263, 2499-2504.	1.8	46
280	Retinal imaging and axonal degeneration in later onset multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 370, 1-6.	0.3	2
281	Altered paired associative stimulation-induced plasticity in NMDAR encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 101-113.	1.7	12
282	Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis. <i>European Journal of Neurology</i> , 2016, 23, 62-67.	1.7	54
283	Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. <i>Brain</i> , 2016, 139, 2641-2652.	3.7	223
284	What is the future of proof of concept studies in multiple sclerosis?. <i>Lancet Neurology</i> , The, 2016, 15, 1107-1109.	4.9	0
285	Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1131-1139.	1.4	17
286	MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e259.	3.1	38
287	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. <i>Journal of Neuroinflammation</i> , 2016, 13, 279.	3.1	351
288	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 280.	3.1	686

#	ARTICLE	IF	CITATIONS
289	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. <i>Journal of Neuroinflammation</i> , 2016, 13, 282.	3.1	217
290	Diagnostic criteria for Susac syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1287-1295.	0.9	184
291	Stress-induced brain activity, brain atrophy, and clinical disability in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13444-13449.	3.3	29
292	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , 2016, 2, e1501678.	4.7	133
293	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 281.	3.1	202
294	Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e286.	3.1	85
295	Visual dysfunction, but not retinal thinning, following anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e198.	3.1	21
296	Power estimation for non-standardized multisite studies. <i>NeuroImage</i> , 2016, 134, 281-294.	2.1	36
297	Placebo-controlled study in neuromyelitis optica—Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016, 22, 862-872.	1.4	63
298	Accuracy and repeatability of two methods of gait analysis — GaitRite™ and Mobility Lab™ in subjects with cerebellar ataxia. <i>Gait and Posture</i> , 2016, 48, 194-201.	0.6	59
299	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. <i>Journal of Neural Transmission</i> , 2016, 123, 439-445.	1.4	32
300	Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e229.	3.1	47
301	Higher-resolution MR elastography reveals early mechanical signatures of neuroinflammation in patients with clinically isolated syndrome. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 51-58.	1.9	47
302	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	2.8	315
303	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 574-584.	4.9	266
304	Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1476-1484.	1.4	33
305	Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. <i>Journal of Neurology</i> , 2016, 263, 575-582.	1.8	53
306	Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in “pattern II multiple sclerosis” and brain biopsy findings in a MOG-IgG-positive case. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1541-1549.	1.4	96

#	ARTICLE	IF	CITATIONS
307	Validity of visual perceptive computing for static posturography in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1596-1606.	1.4	39
308	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e204.	3.1	53
309	Autoantibodies to tetraspanins (CD9, CD81 and CD82) in demyelinating diseases. <i>Journal of Neuroimmunology</i> , 2016, 291, 78-81.	1.1	3
310	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016, 263, 140-149.	1.8	60
311	Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2016, 22, 160-173.	1.4	59
312	Structural Hippocampal Damage Following Anti-N-Methyl-D-Aspartate Receptor Encephalitis. <i>Biological Psychiatry</i> , 2016, 79, 727-734.	0.7	123
313	Afferent Visual Pathway Affection in Patients with PMP22 Deletion-Related Hereditary Neuropathy with Liability to Pressure Palsies. <i>PLoS ONE</i> , 2016, 11, e0164617.	1.1	6
314	Accuracy and Reliability of the Kinect Version 2 for Clinical Measurement of Motor Function. <i>PLoS ONE</i> , 2016, 11, e0166532.	1.1	183
315	Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. <i>Deutsches A&#x0308;rztblatt International</i> , 2016, 113, 879-886.	0.6	14
316	Progressive Multiple Sclerosis (SP and PP MS). , 2016, , 135-150.		0
317	Effects of diazoxide in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e147.	3.1	8
318	Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 196.	3.1	27
319	Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study. <i>BMC Neurology</i> , 2015, 15, 265.	0.8	8
320	Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management. <i>EPMA Journal</i> , 2015, 6, 16.	3.3	36
321	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. <i>Genetic Epidemiology</i> , 2015, 39, 601-608.	0.6	15
322	Periodic limb movements during REM sleep in multiple sclerosis: a previously undescribed entity. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 2323.	1.0	13
323	Comparison of Standard Versus Wide-Field Composite Images of the Corneal Subbasal Layer by In Vivo Confocal Microscopy. , 2015, 56, 5801.		39
324	Sleep Disorders Reduce Health-Related Quality of Life in Multiple Sclerosis (Nottingham Health) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 16, 16514-16528.	1.8	40

#	ARTICLE	IF	CITATIONS
325	Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration. <i>PLoS ONE</i> , 2015, 10, e0128386.	1.1	16
326	Treatment of Chronic Experimental Autoimmune Encephalomyelitis with Epigallocatechin-3-Gallate and Glatiramer Acetate Alters Expression of Heme-Oxygenase-1. <i>PLoS ONE</i> , 2015, 10, e0130251.	1.1	18
327	No Evidence for Retinal Damage Evolving from Reduced Retinal Blood Flow in Carotid Artery Disease. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	21
328	Reliability of Intra-Retinal Layer Thickness Estimates. <i>PLoS ONE</i> , 2015, 10, e0137316.	1.1	75
329	Studying Axonal Outgrowth and Regeneration of the Corticospinal Tract in Organotypic Slice Cultures. <i>Journal of Neurotrauma</i> , 2015, 32, 1465-1477.	1.7	14
330	<i>Toxoplasma gondii</i> seropositivity is negatively associated with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 285, 119-124.	1.1	22
331	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	4.5	59
332	Does Nrf2 help nerves to survive?. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015, 2, e105.	3.1	0
333	7T MRI in natalizumab-associated PML and ongoing MS disease activity. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015, 2, e171.	3.1	20
334	Tracking CNS and systemic sources of oxidative stress during the course of chronic neuroinflammation. <i>Acta Neuropathologica</i> , 2015, 130, 799-814.	3.9	76
335	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2015, 21, 678-688.	1.4	209
336	Optic radiation damage in multiple sclerosis is associated with visual dysfunction and retinal thinning – an ultrahigh-field MR pilot study. <i>European Radiology</i> , 2015, 25, 122-131.	2.3	84
337	Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 487-495.	2.2	64
338	Pushing the boundaries of neuromyelitis optica. <i>Neurology</i> , 2015, 85, 118-119.	1.5	14
339	Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. <i>Journal of Neurology</i> , 2015, 262, 1379-1384.	1.8	47
340	The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis. <i>Current Treatment Options in Neurology</i> , 2015, 17, 354.	0.7	51
341	Assessing Mitochondrial Movement Within Neurons: Manual Versus Automated Tracking Methods. <i>Traffic</i> , 2015, 16, 906-917.	1.3	25
342	MRI characteristics of neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2015, 84, 1165-1173.	1.5	523

#	ARTICLE	IF	CITATIONS
343	Iridodonesis as a cause of recurrent vertigo. <i>Neurology</i> , 2015, 85, 1353-1353.	1.5	0
344	Cerebellar neurochemical alterations in spinocerebellar ataxia type 14 appear to include glutathione deficiency. <i>Journal of Neurology</i> , 2015, 262, 1927-1935.	1.8	13
345	Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. <i>Neurology</i> , 2015, 85, 521-527.	1.5	24
346	Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. <i>Neurology</i> , 2015, 85, 610-618.	1.5	50
347	Temporal retinal nerve fibre layer thinning in cluster headache patients detected by optical coherence tomography. <i>Cephalgia</i> , 2015, 35, 946-958.	1.8	10
348	Association of serum Epstein-Barr nuclear antigen-1 antibodies and intrathecal immunoglobulin synthesis in early multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 285, 156-160.	1.1	21
349	Signaling networks in MS: A systems-based approach to developing new pharmacological therapies. <i>Multiple Sclerosis Journal</i> , 2015, 21, 138-146.	1.4	24
350	Vessel Labeling in Combined Confocal Scanning Laser Ophthalmoscopy and Optical Coherence Tomography Images: Criteria for Blood Vessel Discrimination. <i>PLoS ONE</i> , 2014, 9, e102034.	1.1	12
351	Multimodal Retinal Vessel Analysis in CADASIL Patients. <i>PLoS ONE</i> , 2014, 9, e112311.	1.1	26
352	Optical coherence tomography for retinal imaging in multiple sclerosis. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2014, 4, 153.	0.7	18
353	Retinal Segmentation to Demonstrate Hyperplasia in Ataxia of Charlevoix-Saguenay: Critique on Study Methodology and Results. , 2014, 55, 4728.		1
354	Detailing intra-lesional venous lumen shrinking in multiple sclerosis investigated by sFLAIR MRI at 7-T. <i>Journal of Neurology</i> , 2014, 261, 2032-2036.	1.8	17
355	Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 49.	4.4	22
356	Dynamic formation of macular microcysts independent of vitreous traction changes. <i>Neurology</i> , 2014, 83, 73-77.	1.5	47
357	Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. <i>Journal of Neuroinflammation</i> , 2014, 11, 129.	3.1	24
358	Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 411-418.	0.9	63
359	The activity of catechol-O-methyltransferase (COMT) is not impaired by high doses of epigallocatechin-3-gallate (EGCG) in vivo. <i>European Journal of Pharmacology</i> , 2014, 740, 645-651.	1.7	45
360	Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. <i>Journal of Neuroinflammation</i> , 2014, 11, 46.	3.1	100

#	ARTICLE	IF	CITATIONS
361	Effects of Deep Repetitive Transcranial Magnetic Stimulation on Brain-Derived Neurotrophic Factor Serum Concentration in Healthy Volunteers. <i>Neuropsychobiology</i> , 2014, 69, 112-119.	0.9	12
362	Metabolic Evidence for Cerebral Neurodegeneration in Spinocerebellar Ataxia Type 1. <i>Cerebellum</i> , 2014, 13, 199-206.	1.4	14
363	Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis. <i>BMC Neurology</i> , 2014, 14, 31.	0.8	46
364	Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2014, 76, 792-801.	2.8	82
365	Retinal nerve fibre layer thickness correlates with brain white matter damage in multiple sclerosis: A combined optical coherence tomography and diffusion tensor imaging study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1904-1907.	1.4	36
366	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). <i>Journal of Neurology</i> , 2014, 261, 1-16.	1.8	494
367	Chronic cerebrospinal venous insufficiency in multiple sclerosis: the final curtain. <i>Lancet</i> , The, 2014, 383, 106-108.	6.3	14
368	Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. <i>Multiple Sclerosis Journal</i> , 2014, 20, 295-303.	1.4	115
369	Complement regulatory proteins (CD46, 55 and 59) expressed on Schwann cells: Immune targets in demyelinating neuropathies?. <i>Journal of Neuroimmunology</i> , 2014, 276, 172-174.	1.1	8
370	Identical lesion morphology in primary progressive and relapsing-remitting MS – an ultrahigh field MRI study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1866-1871.	1.4	40
371	Reply to: Photoreceptor layer thinning in Parkinsonian syndromes. <i>Movement Disorders</i> , 2014, 29, 1223-1224.	2.2	2
372	Oxidative damage to mitochondria at the nodes of Ranvier precedes axon degeneration in ex vivo transected axons. <i>Experimental Neurology</i> , 2014, 261, 127-135.	2.0	37
373	The investigation of acute optic neuritis: a review and proposed protocol. <i>Nature Reviews Neurology</i> , 2014, 10, 447-458.	4.9	248
374	Increased Catabolic State in Spinocerebellar Ataxia Type 1 Patients. <i>Cerebellum</i> , 2014, 13, 440-446.	1.4	17
375	Using perceptive computing in multiple sclerosis - the Short Maximum Speed Walk test. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2014, 11, 89.	2.4	47
376	Neuromyelitis optica: clinical features, immunopathogenesis and treatment. <i>Clinical and Experimental Immunology</i> , 2014, 176, 149-164.	1.1	277
377	Visual evoked potentials in neuromyelitis optica and its spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2014, 20, 617-620.	1.4	47
378	Multiple sclerosis: The elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1. <i>Journal of Neuroimmunology</i> , 2014, 272, 56-61.	1.1	34

#	ARTICLE	IF	CITATIONS
379	Sleep disorders in multiple sclerosis and their relationship to fatigue. <i>Sleep Medicine</i> , 2014, 15, 5-14.	0.8	101
380	Photoreceptor layer thinning in idiopathic Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1163-1170.	2.2	84
381	Optimal management of multiple sclerosis during pregnancy: current perspectives. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2014, 4, 111.	0.7	4
382	High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 822-832.	1.7	114
383	Pregnancy in Multiple Sclerosis: A Questionnaire Study. <i>PLoS ONE</i> , 2014, 9, e99106.	1.1	9
384	Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 112.	0.7	46
385	Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?. <i>EPMA Journal</i> , 2013, 4, 5.	3.3	80
386	Can we prevent or treat multiple sclerosis by individualised vitamin D supply?. <i>EPMA Journal</i> , 2013, 4, 4.	3.3	44
387	Treatment of sleep disorders may improve fatigue in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1826-1830.	0.6	63
388	Progressive multiple sclerosis: desperately seeking remedy. <i>Lancet Neurology</i> , The, 2013, 12, 840-841.	4.9	2
389	Cerebral magnetic resonance elastography in supranuclear palsy and idiopathic Parkinson's disease. <i>NeuroImage: Clinical</i> , 2013, 3, 381-387.	1.4	76
390	A blood based 12-miRNA signature of Alzheimer disease patients. <i>Genome Biology</i> , 2013, 14, R78.	13.9	438
391	Tumefactive multiple sclerosis and fingolimod. <i>Neurology</i> , 2013, 81, 1648-1649.	1.5	8
392	Cladribine in multiple sclerosis: pitfalls in a new treatment landscape. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1-3.	0.9	1
393	Periventricular venous density in multiple sclerosis is inversely associated with T2 lesion count: a 7 Tesla MRI study. <i>Multiple Sclerosis Journal</i> , 2013, 19, 316-325.	1.4	52
394	Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation. <i>Journal of Neuroimmunology</i> , 2013, 254, 165-169.	1.1	30
395	The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse. <i>Journal of Neuroimmunology</i> , 2013, 262, 66-71.	1.1	31
396	Characteristics of Susac syndrome: a review of all reported cases. <i>Nature Reviews Neurology</i> , 2013, 9, 307-316.	4.9	293

#	ARTICLE	IF	CITATIONS
397	Functional and structural brain changes in anti- α -methylglutamate receptor encephalitis. <i>Annals of Neurology</i> , 2013, 74, 284-296.	2.8	167
398	Hope for a rare disease: eculizumab in neuromyelitis optica. <i>Lancet Neurology</i> , The, 2013, 12, 529-531.	4.9	13
399	Low contrast visual acuity testing is associated with cognitive performance in multiple sclerosis: a cross-sectional pilot study. <i>BMC Neurology</i> , 2013, 13, 167.	0.8	37
400	T-cell homeostasis in pediatric multiple sclerosis. <i>Neurology</i> , 2013, 81, 784-792.	1.5	62
401	Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. <i>Multiple Sclerosis Journal</i> , 2013, 19, 443-450.	1.4	100
402	Bilateral vertebral artery dissection, agenesis of both ICAs, and connective tissue aberrations. <i>Neurology</i> , 2013, 80, 1442-1443.	1.5	4
403	Higher macular volume in patients with MS receiving fingolimod. <i>Neurology</i> , 2013, 80, 128-129.	1.5	20
404	Are there Epstein-Barr virus seronegative patients with multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1242-1243.	1.4	13
405	Breastfeeding is associated with lower risk for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 553-558.	1.4	53
406	Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. <i>Neurology</i> , 2013, 81, 1966-1966.	1.5	17
407	Olfactory Dysfunction in Patients with Neuromyelitis Optica. <i>Multiple Sclerosis International</i> , 2013, 2013, 1-4.	0.4	19
408	Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2013, 20, 1170-1176.	1.7	45
409	What Went Wrong? the Flawed Concept of Cerebrospinal Venous Insufficiency. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 657-668.	2.4	51
410	Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1887-1895.	1.4	141
411	Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon- γ Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2013, 8, e70626.	1.1	43
412	Optic Neuritis Is Associated with Inner Nuclear Layer Thickening and Microcystic Macular Edema Independently of Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e71145.	1.1	102
413	Enlargement of Cerebral Ventricles as an Early Indicator of Encephalomyelitis. <i>PLoS ONE</i> , 2013, 8, e72841.	1.1	22
414	Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e66151.	1.1	162

#	ARTICLE	IF	CITATIONS
415	Concomitant amyotrophic lateral sclerosis and paraclinical laboratory features of multiple sclerosis: coincidence or causal relationship?. <i>BMJ Case Reports</i> , 2013, 2013, bcr2012007975-bcr2012007975.	0.2	4
416	Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. <i>British Journal of Ophthalmology</i> , 2012, 96, 62-67.	2.1	68
417	Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. <i>Neurology</i> , 2012, 79, 708-714.	1.5	190
418	Multiple Sclerosis Lesions and Irreversible Brain Tissue Damage. <i>Archives of Neurology</i> , 2012, 69, 739-45.	4.9	68
419	Fatigue in multiple sclerosis: which patient should be referred to a sleep specialist?. <i>Multiple Sclerosis Journal</i> , 2012, 18, 248-249.	1.4	34
420	Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2012, 69, 239.	4.9	276
421	Is It Too Early to Predict the Failure of Natalizumab in NMO?â€™Reply. <i>Archives of Neurology</i> , 2012, 69, 1085.	4.9	4
422	Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-10.	0.4	111
423	Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. <i>Therapeutic Advances in Neurological Disorders</i> , 2012, 5, 75-79.	1.5	39
424	Can we overcome the â€™clinico-radiological paradoxâ€™™ in multiple sclerosis?. <i>Journal of Neurology</i> , 2012, 259, 2151-2160.	1.8	45
425	Dynamics of saccade parameters in multiple sclerosis patients with fatigue. <i>Journal of Neurology</i> , 2012, 259, 2656-2663.	1.8	48
426	Fatigue and sleep disorders in multiple sclerosis: is obstructive sleep apnea a link?. <i>Sleep and Breathing</i> , 2012, 16, 949-950.	0.9	0
427	Exercise in multiple sclerosis – an integral component of disease management. <i>EPMA Journal</i> , 2012, 3, 2.	3.3	63
428	Magnetic resonance elastography reveals altered brain viscoelasticity in experimental autoimmune encephalomyelitis. <i>NeuroImage: Clinical</i> , 2012, 1, 81-90.	1.4	99
429	Fatigue in multiple sclerosis: a diagnostic and therapeutic challenge. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 791-793.	0.9	11
430	Efficacy of vision restoration therapy after optic neuritis (VISION study): study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 94.	0.7	8
431	Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. <i>EPMA Journal</i> , 2012, 3, 9.	3.3	59
432	Multi-scale classification of disease using structural MRI and wavelet transform. <i>NeuroImage</i> , 2012, 62, 48-58.	2.1	61

#	ARTICLE	IF	CITATIONS
433	Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1592-1599.	1.4	132
434	Brain Viscoelasticity Alteration in Chronic-Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e29888.	1.1	195
435	Is Metabolic Flexibility Altered in Multiple Sclerosis Patients?. <i>PLoS ONE</i> , 2012, 7, e43675.	1.1	50
436	Optic Nerve Head Quantification in Idiopathic Intracranial Hypertension by Spectral Domain OCT. <i>PLoS ONE</i> , 2012, 7, e36965.	1.1	68
437	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. <i>Journal of Neuroinflammation</i> , 2012, 9, 14.	3.1	593
438	Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 15.	0.7	79
439	Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS. <i>PLoS ONE</i> , 2012, 7, e38741.	1.1	52
440	Mitoxantrone Induces Natural Killer Cell Maturation in Patients with Secondary Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e39625.	1.1	21
441	The German Healthcare System. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2012, , 45-67.	0.6	1
442	Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1067-1073.	1.4	144
443	Imaging the Visual Pathway in Neuromyelitis Optica. <i>Multiple Sclerosis International</i> , 2011, 2011, 1-5.	0.4	22
444	Metabolic Changes in the Visual Cortex Are Linked to Retinal Nerve Fiber Layer Thinning in Multiple Sclerosis. <i>PLoS ONE</i> , 2011, 6, e18019.	1.1	76
445	MRI Pattern Recognition in Multiple Sclerosis Normal-Appearing Brain Areas. <i>PLoS ONE</i> , 2011, 6, e21138.	1.1	46
446	Perfluorocarbon Particle Size Influences Magnetic Resonance Signal and Immunological Properties of Dendritic Cells. <i>PLoS ONE</i> , 2011, 6, e21981.	1.1	45
447	Temporal Retinal Nerve Fiber Loss in Patients with Spinocerebellar Ataxia Type 1. <i>PLoS ONE</i> , 2011, 6, e23024.	1.1	57
448	The Influence of Physiological Aging and Atrophy on Brain Viscoelastic Properties in Humans. <i>PLoS ONE</i> , 2011, 6, e23451.	1.1	145
449	Environmental factors in early childhood are associated with multiple sclerosis: a case-control study. <i>BMC Neurology</i> , 2011, 11, 123.	0.8	27
450	The German healthcare system. <i>EPMA Journal</i> , 2010, 1, 535-547.	3.3	24

#	ARTICLE	IF	CITATIONS
451	No cerebrocervical venous congestion in patients with multiple sclerosis. <i>Annals of Neurology</i> , 2010, 68, 173-183.	2.8	236
452	No Evidence for XMRV in German CFS and MS Patients with Fatigue Despite the Ability of the Virus to Infect Human Blood Cells In Vitro. <i>PLoS ONE</i> , 2010, 5, e15632.	1.1	50
453	Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study. <i>Multiple Sclerosis Journal</i> , 2010, 16, 893-896.	1.4	65
454	Attention Network Test reveals alerting network dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 93-99.	1.4	68
455	Correlation of self-assessed fatigue and alertness in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1134-1140.	1.4	88
456	Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. <i>Journal of the Neurological Sciences</i> , 2010, 298, 158-162.	0.3	169
457	Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. <i>Journal of Neuroinflammation</i> , 2010, 7, 52.	3.1	182
458	Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. <i>Neurochemistry International</i> , 2010, 57, 662-667.	1.9	15
459	Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 647-652.	0.6	107
460	MR-elastography reveals degradation of tissue integrity in multiple sclerosis. <i>NeuroImage</i> , 2010, 49, 2520-2525.	2.1	262
461	Encephalopathy, visual disturbance and hearing loss—recognizing the symptoms of Susac syndrome. <i>Nature Reviews Neurology</i> , 2009, 5, 683-688.	4.9	59
462	SEVERE CARDIAC FAILURE IN A PATIENT WITH MULTIPLE SCLEROSIS FOLLOWING LOW-DOSE MITOXANTRONE TREATMENT. <i>Neurology</i> , 2009, 73, 991-993.	1.5	38
463	Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Annals of Neurology</i> , 2009, 66, 310-322.	2.8	151
464	A woman with acute myelopathy in pregnancy: case presentation. <i>BMJ: British Medical Journal</i> , 2009, 339, b3862-b3862.	2.4	6
465	A woman with acute myelopathy in pregnancy: case progression. <i>BMJ: British Medical Journal</i> , 2009, 339, b4025-b4025.	2.4	2
466	A woman with acute myelopathy in pregnancy: case outcome. <i>BMJ: British Medical Journal</i> , 2009, 339, b4026-b4026.	2.4	31
467	Treatment-resistant chronic headaches and focal pachymeningitis in a 46-year-old man: a rare presentation of Wegener's granulomatosis. <i>Lancet Neurology</i> , The, 2008, 7, 368-372.	4.9	12
468	Multiple sclerosis following etanercept treatment for ankylosing spondylitis. <i>Scandinavian Journal of Rheumatology</i> , 2008, 37, 397-399.	0.6	34

#	ARTICLE	IF	CITATIONS
469	Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 202-214.	2.7	286
470	Perivascular spaces--MRI marker of inflammatory activity in the brain?. <i>Brain</i> , 2008, 131, 2332-2340.	3.7	200
471	Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2008, 3, e1928.	1.1	110
472	Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2007, 16, 479-484.	0.9	20
473	Cerebral blood perfusion changes in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2007, 259, 16-20.	0.3	52
474	Revised diagnostic criteria for neuromyelitis optica--incorporation of NMO-IgG status. <i>Nature Clinical Practice Neurology</i> , 2007, 3, E1-E1.	2.7	15
475	Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica. <i>PLoS Medicine</i> , 2007, 4, e133.	3.9	187
476	Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon-1a. <i>World Journal of Gastroenterology</i> , 2007, 13, 3638.	1.4	33
477	Bilateral meralgia paresthetica after cesarian section with epidural analgesia. <i>Journal of the Peripheral Nervous System</i> , 2006, 11, 98-99.	1.4	9
478	Postural hand tremor before and following liver transplantation and immunosuppression with cyclosporine or tacrolimus in patients without clinical signs of hepatic encephalopathy. <i>Clinical Transplantation</i> , 2004, 18, 429-433.	0.8	17
479	Levetiracetam in Focal Epilepsy and Hepatic Porphyria: A Case Report. <i>Epilepsia</i> , 2004, 45, 559-560.	2.6	37
480	Optical coherence tomography in neurodegenerative and other neurologic diseases. , 0, , 128-144.		0